Eli Lilly’s GLP-1 telehealth ecosystem is drawing fresh conflict-of-interest questions after Oura agreed to buy Counsel Health, the platform Lilly lists for patients seeking GLP-1 prescriptions. The acquisition would expand Counsel clinicians’ access to ring-collected data from Oura, potentially tightening the link between Lilly’s promoted provider network and a data platform with corporate ownership incentives. Lilly also agreed to buy $50 million in Oura stock subject to conditions that the report says have not been met yet. For biotech and medtech stakeholders, the story adds to regulatory and governance scrutiny around downstream use of patient data and financial interests that can emerge when manufacturers promote treatment pathways through third-party digital health companies.